UPDATED: A patient in Akashi’s suspended Duchenne MD trial dies

John Carroll

A little more than a week after Cambridge, MA-based Akashi Therapeutics its study of a new drug for muscular dystrophy after a was sent to the hospital, the biotech reports that the subject has died.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS